Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 4Strabismus 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms 1Leukemia 1Emergence Delirium 1Drug-Related Side Effects and Adverse Reactions 1Autoimmune Diseases 1

Interventions

telitacicept 3fludarabine 3Prednisone 3Cyclophosphamide 3Specimen Handling 2Nivolumab 2Antilymphocyte Serum 2thymoglobulin 1remdesivir 1prednylidene 1deltacortene 1carmustine, poliferprosan 20 drug combination 1cabozantinib 1Vitamin D 1Valsartan 1Pyridostigmine Bromide 1Population Groups 1Platinum Compounds 1Plasma Exchange 1Peripheral Blood Stem Cell Transplantation 1Music Therapy 1Melphalan 1Ipilimumab 1Infliximab 1Immunoglobulins, Intravenous 1Hydroxychloroquine 1Fish Oils 1Fatty Acids, Omega-3 1Etoposide 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Autoimmune Diseases × Pyridostigmine Bromide × Clear all
NCT06723548 2024-12-09

Telitacicept and Low-dose Steroids in Refractory Myasthenia Gravis

First Affiliated Hospital of Wenzhou Medical University

Phase 4 Not yet recruiting
30 enrolled

Autoimmune Diseases, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡